Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors

NCT07670312 is registered in ClinicalTrials.gov with XYone Therapeutics, Inc as lead sponsor.

NCT NCT07670312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07670312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors
Lead sponsor
XYone Therapeutics, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 17, 2026
Completion date
September 15, 2030
Enrollment
190 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastric cancer, gej adenocarcinoma, muc1-expressing advanced, relapsed and/or refractory solid tumors, non-small cell lung cancer, ovarian cancer, pancreatic adenocarcinoma